India has released the 10th edition of its official drug standards book, Indian Pharmacopoeia 2026. The update adds 121 new monographs, taking the total to 3,340. It also reflects India’s rising role in global pharmacovigilance and its growing recognition in international medicines regulation.
Key Features of the New Edition
- The new edition includes 121 additional monographs.
- The total number of monographs has risen to 3,340.
- The update covers medicines, formulations and quality standards.
- It strengthens the national framework for drug regulation and testing.
First Inclusion of Blood Components
- For the first time, 20 blood component monographs have been included.
- This is expected to support research in blood transfusion.
- It is also relevant for thalassemia, haemophilia and anaemia management.
- India has become the first country to include blood components in this format.
Public Health and Programme Linkages
- The new monographs are expected to support the National TB Elimination Programme.
- They are also relevant for Anaemia Mukt Bharat.
- The Universal Immunisation Programme may also benefit from improved standards.
- Stronger pharmacopoeial standards can improve the safety and quality of medicines used in public health systems.
Global Significance
- India now ranks 8th globally in WHO pharmacovigilance contributions.
- This is a major rise from 123rd position a decade ago.
- The Indian Pharmacopoeia is now recognised in 19 Global South countries.
- This reflects India’s growing influence in medicines standards and drug safety.